パーキンソン病治療薬の世界市場予測（～2022年）：カルビドパ/レボドパ、ドパミン受容体刺激薬、MAO阻害薬...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.2.1 MARKETS COVERED 13
1.2.2 YEARS CONSIDERED FOR THE STUDY 13
1.3 CURRENCY 14
1.4 LIMITATIONS 14
1.5 STAKEHOLDERS 14

2 RESEARCH METHODOLOGY 15
2.1 RESEARCH DATA 16
2.1.1 SECONDARY DATA 16
2.1.1.1 Key data from secondary sources 16
2.1.2 PRIMARY DATA 17
2.1.2.1 Key data from primary sources 18
2.2 MARKET SIZE ESTIMATION 18
2.2.1 BOTTOM-UP APPROACH 19
2.2.2 TOP-DOWN APPROACH 20
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.4 ASSUMPTIONS FOR THE STUDY 22

3 EXECUTIVE SUMMARY 23

4 PREMIUM INSIGHTS 27
4.1 PARKINSON’S DISEASE TREATMENT MARKET OVERVIEW 27
4.2 GEOGRAPHIC ANALYSIS: PARKINSON’S DISEASE TREATMENT MARKET,
BY DRUG CLASS 28
4.3 GEOGRAPHIC ANALYSIS OF THE PARKINSON’S DISEASE TREATMENT MARKET,
BY COUNTRY 29
4.4 GEOGRAPHIC ANALYSIS OF THE PARKINSON’S DISEASE TREATMENT MARKET 30

5 MARKET OVERVIEW 31
5.1 INTRODUCTION 31
5.2 MARKET DYNAMICS 31
5.2.1 DRIVERS 32
5.2.1.1 Growth in aging population and the associated increase in the prevalence of Parkinson’s disease 32
5.2.1.2 Government funding for research 32
 
5.2.2 RESTRAINTS 33
5.2.2.1 Availability of alternative treatments 33
5.2.3 OPPORTUNITIES 34
5.2.3.1 Patent expiry of branded drugs 34
5.2.3.2 Strong drug pipeline 34

6 PARKINSON’S DISEASE TREATMENT MARKET, BY DRUG CLASS 36
6.1 INTRODUCTION 37
6.2 CARBIDOPA/LEVODOPA 37
6.3 DOPAMINE RECEPTOR AGONISTS 39
6.4 MAO INHIBITORS 40
6.5 COMT INHIBITORS 42
6.6 ANTICHOLINERGICS 43
6.7 OTHER DRUGS 45

7 PARKINSON’S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 47
7.1 INTRODUCTION 48
7.2 HOSPITAL PHARMACIES 49
7.3 RETAILER PHARMACIES 50
7.4 ONLINE PHARMACIES 51

8 PARKINSON’S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING 52
8.1 INTRODUCTION 53
8.2 HOSPITALS 54
8.3 CLINICS 55

9 PARKINSON’S DISEASE TREATMENT MARKET, BY REGION 57
9.1 INTRODUCTION 58
9.2 EUROPE 59
9.3 NORTH AMERICA 61
9.3.1 U.S. 63
9.3.2 CANADA 65
9.4 ASIA 67
9.4.1 JAPAN 69
9.4.2 CHINA 71
9.4.3 REST OF ASIA 73
9.5 REST OF THE WORLD 75
 

10 COMPANY PROFILES 77
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
10.1 GSK 77
10.2 MERCK 79
10.3 NOVARTIS 81
10.4 TEVA 83
10.5 BOEHRINGER INGELHEIM 86
10.6 IMPAX 88
10.7 ABBVIE 90
10.8 VALEANT PHARMACEUTICALS 92
10.9 LUNDBECK 94
10.10 SUN PHARMA 96
10.11 WOCKHARDT 98
10.12 ACADIA 100
10.13 UCB 102

*Details on MarketsandMarkets view, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments might not be captured in case of unlisted companies.

11 APPENDIX 105
11.1 INSIGHTS OF INDUSTRY EXPERTS 105
11.2 DISCUSSION GUIDE 106
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 108
11.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 110
11.5 AVAILABLE CUSTOMIZATIONS 111
11.6 RELATED REPORTS 112
11.7 AUTHOR DETAILS 113